Kangsheng Global (09960) released interim results with revenue of 474 million yuan, a year-on-year increase of 3.7%, and the tumor testing sector achieved significant growth

According to the Zhitong Finance App, Kangsheng Global (09960) announced results for the six months ended June 30, 2026. The group achieved revenue of 474 million yuan during the period, up 3.7% year on year; gross profit of 218 million yuan, up 10.9% year on year; loss due to parent company owners of 18.864 million yuan; basic loss of 1.89 points per share.

According to the announcement, revenue growth was mainly due to the stable performance of the core sector and the rapid expansion of the tumor testing sector. Among them, the oncology testing sector has benefited from deep collaboration between the target of the acquisition and the existing business in terms of channels, technology and customer resources, and has achieved significant growth and has become the Group's new growth engine; hematology testing, as the core sector, continues to play the role of ballast stone and remains stable.

The increase in gross margin was mainly due to the increase in revenue, the release of synergy effects of acquisitions, and the Group's continuous promotion of organizational structure optimization and human resource allocation adjustments. Strict cost control measures were effective. Employee costs and other operating costs decreased by about 5.7% and 7.9%, respectively. Raw materials increased in line with the expansion of business scale, the overall cost structure continued to be optimized, and profitability steadily increased.

In the first half of 2026, Kangsheng Global showed strong business resilience and clear strategic strength in the macro environment of normalization of compliance in the medical industry and the deepening demand for accurate diagnosis and treatment. Facing deep changes in the industry structure, the Group continues to build a strong operating chassis by relying on the synergetic advantages of multiple technology platforms and a professional service network covering the whole country. Hematology testing, as a traditional field of advantage, continues to play a “ballast stone” role and stabilizes the market base; at the same time, the “large tumors” strategic sector created by the Group's forward-looking vision ushered in a critical inflection point. The full course of the disease from early screening, accurate diagnosis and classification, and accompanying diagnosis to recurrence monitoring gradually formed in a closed loop, and the synergy of non-hematology specialty matrices was increasingly evident. In the first half of 2026, the revenue from the all-sector co-construction business once again achieved rapid growth, reaching 46%. Through a “balanced offense and defense” business layout, the Group has effectively resisted the risk of policy and market fluctuations, and has achieved a steady upgrade of the business structure to high added value, compliance, reagents and service two-wheel drive.